Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07678580 Tislelizumab Locally Advanced Esophageal Squamous Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into NCT07678580, evaluating Tislelizumab in Locally Advanced Esophageal Squamous Cell Carcinoma: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
JPRN-jRCT2021260021 Durvalumab Hepatitis B Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into JPRN-jRCT2021260021, evaluating Durvalumab in Hepatitis B: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
NCT07677683 Pixofisiran/Lixadesiran Unmet-Need Clinical Development Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into NCT07677683, evaluating Pixofisiran/Lixadesiran in Unmet-Need Clinical Development: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
NCT07678931 Stapokibart Rhinitis, Allergic, Seasonal Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into NCT07678931, evaluating Stapokibart in Rhinitis, Allergic, Seasonal: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
NCT07679607 SOC Radiation Treatment Planning Radiation Pneumonitis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into NCT07679607, evaluating SOC Radiation Treatment Planning in Radiation Pneumonitis: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
CTR20262483 Trastuzumab Brengitecan Hormone receptor positive HER2 positive breast cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into CTR20262483, evaluating Trastuzumab Brengitecan in Hormone receptor positive HER2 positive breast cancer: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
CTR20262467 Trastuzumab Rezetecan Adenocarcinoma of large intestine Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into CTR20262467, evaluating Trastuzumab Rezetecan in Adenocarcinoma of large intestine: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
CTR20262431 Palverafusp α Advanced Hepatocellular Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into CTR20262431, evaluating Palverafusp α in Advanced Hepatocellular Carcinoma: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
CTR20262538 QLS7305 Idiopathic Membranous Glomerulonephritis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into CTR20262538, evaluating QLS7305 in Idiopathic Membranous Glomerulonephritis: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
CTR20262561 Topiroxostat Hyperuricemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into CTR20262561, evaluating Topiroxostat in Hyperuricemia: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
CTR20262556 DXC-006 Astrocytoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into CTR20262556, evaluating DXC-006 in Astrocytoma: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
CTR20262619 KH658 Diabetic macular oedema Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into CTR20262619, evaluating KH658 in Diabetic macular oedema: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.